Patents by Inventor Masayuki Tsuchiya

Masayuki Tsuchiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120015402
    Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.
    Type: Application
    Filed: July 21, 2011
    Publication date: January 19, 2012
    Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, CIEA INTERNATIONAL INC., PHARMALOGICALS RESEARCH PTE. LTD.
    Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
  • Publication number: 20120015436
    Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.
    Type: Application
    Filed: September 6, 2011
    Publication date: January 19, 2012
    Inventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
  • Patent number: 8034903
    Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: October 11, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
  • Patent number: 8008076
    Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: August 30, 2011
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Pharmalogicals Research Pte. Ltd., CIEA International Inc.
    Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
  • Patent number: 8008073
    Abstract: Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: August 30, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
  • Patent number: 7993642
    Abstract: Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: August 9, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
  • Publication number: 20110070614
    Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.
    Type: Application
    Filed: November 23, 2010
    Publication date: March 24, 2011
    Inventors: MASAYUKI TSUCHIYA, SHIGEYUKI IIJIMA, IZUMI SUGO, YASUO SEKIMORI, KENJU UENO, KIYOSHI HABU
  • Publication number: 20110059488
    Abstract: Anti-human Mpl antibodies were isolated and purified, and then anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were purified using genetic engineering techniques. Furthermore, the present inventors succeeded in humanizing anti-human Mpl sc(Fv)2. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.
    Type: Application
    Filed: September 2, 2010
    Publication date: March 10, 2011
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
  • Patent number: 7892543
    Abstract: The invention provides a reshaped human anti-HM 1.24 antibody having: (A) an L chain having (1) the C region of a human L chain, and (2) the V region of an L chain having the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. This reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, and the reshaped human antibody of the present invention has a low antigenicity and can be used for medical treatment.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: February 22, 2011
    Assignee: Chugai Seiyako Kabushiki Kaisha
    Inventors: Koichiro Ono, Toshihiko Ohtomo, Masayuki Tsuchiya, Yasushi Yoshimura, Yasuo Koishihara, Masaaki Kosaka
  • Publication number: 20110002922
    Abstract: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.
    Type: Application
    Filed: April 26, 2010
    Publication date: January 6, 2011
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Tetsuo Nakamura, Masayuki Tsuchiya
  • Patent number: 7863042
    Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: January 4, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kenju Ueno, Kiyoshi Habu
  • Publication number: 20100172899
    Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.
    Type: Application
    Filed: March 18, 2010
    Publication date: July 8, 2010
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
  • Patent number: 7744880
    Abstract: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: June 29, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Tetsuo Nakamura, Masayuki Tsuchiya
  • Patent number: 7709615
    Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: May 4, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
  • Patent number: 7696325
    Abstract: This invention relates to reconstructed polypeptides which have properties of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination. The reconstructed polypeptides comprise two or more H chain V regions and two or more L chain V regions of a monoclonal antibody which induces apoptosis of nucleated blood cells having IAP. The reconstructed polypeptides are useful as a therapeutic agent for blood dyscrasia such as leukemia.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: April 13, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Naoshi Fukushima, Masayuki Tsuchiya, Masayoshi Oh-Eda, Shinsuke Uno, Yasufumi Kikuchi
  • Patent number: 7691588
    Abstract: The present inventors used antibody engineering techniques to prepare functional antibodies that correspond to individual mutations in causative genes of diseases, and discovered that such antibodies enable the treatment of the diseases. Specifically, the inventors succeeded in preparing ligands, particularly minibodies, which have agonistic activity to receptors that have almost completely lost responsiveness to their natural ligands because of gene mutations (for example, a thrombopoietin (TPO) receptor whose reactivity to TPO has been markedly impaired), and which can transduce signals by interacting with these mutant receptors at levels comparable to normal.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: April 6, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Yuichi Hirata
  • Patent number: 7666610
    Abstract: Methods for measuring transporter activity using budding baculoviruses that do not express endogenous transporters on their envelope have a low background level and can measure the target activity with a high sensitivity. Such methods can be used to measure functional changes due to transporter SNPs over a more extensive range of substrates, and can be applied to tailor-made therapies.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: February 23, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Ryoichi Saitoh, Toshihiko Ohtomo, Masayuki Tsuchiya
  • Publication number: 20090311718
    Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. The modified antibody can be used as a signal transduction agonist and, therefore, useful as a preventive and/or remedy for various diseases such as cancer, inflammation, hormone disorders and blood diseases.
    Type: Application
    Filed: July 2, 2009
    Publication date: December 17, 2009
    Inventors: Naoshi Fukushima, Masayuki Tsuchiya, Shinsuke Uno, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunod
  • Patent number: 7563599
    Abstract: The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: July 21, 2009
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Toshihiko Ohtomo, Koh Sato, Masayuki Tsuchiya
  • Publication number: 20090061485
    Abstract: The present invention relates to a method of producing a recombinant protein, particularly an antibody, using a cell in which the function of a fucose transporter is inhibited, and it also provides a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed.
    Type: Application
    Filed: December 22, 2004
    Publication date: March 5, 2009
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kiyoshi Habu, Masamichi Sugimoto